Vyvanse, or its generic counterpart lisdexamfetamine dimesylate, is prescribed to treat ADHD in adults, and children six years of age or older, as well as moderate to sever binge eating disorder (BED) ...

As medications used to treat ADHD have endured a years-long shortage, generic versions of popular ADHD medications have been prescribed with increasing frequency for patients in need. Yet, the ...

To address the nationwide shortage of medications for attention-deficit/hyperactivity disorder, the Drug Enforcement Administration is allowing an increase in the ...

Supply from drugmakers for the stimulant medications most commonly prescribed for ADHD are still falling short of demand, the Food and Drug Administration says, and many Americans who rely on these ...

Whenever a vitally important drug is recalled, there is a major cause for concern that countless users' health needs are not being met. Yet again in 2025, a generic version of a popular ADHD ...

Co announced that VYVANSE (lisdexamfetamine dimesylate) effectively controlled Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children aged 6 to 12 years ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products ...